Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 1/2018

01-01-2018 | Therapy Review

Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review

Authors: Jurgen Sota, Donato Rigante, Giuseppe Lopalco, Bruno Frediani, Rossella Franceschini, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Claudia Fabiani, Luca Cantarini

Published in: Rheumatology International | Issue 1/2018

Login to get access

Abstract

Intraocular inflammation is one of the more relevant complications of Behçet’s disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.
Literature
1.
Yazici H, Ugurlu S, Seyahi E (2012) Behçet syndrome: is it one condition? Clin Rev Allergy Immunol 43:275–280CrossRefPubMed
2.
Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14:1–18PubMed
3.
Behçet H, Matteson EL (2010) On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus-1937. Clin Exp Rheumatol 28(4 Suppl 60):S2–S5PubMed
4.
Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef
5.
Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67:1656–1662CrossRefPubMed
6.
Vitale A, Emmi G, Lopalco G et al (2017) Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease. Clin Rheumatol. doi:10.​1007/​s10067-017-3627-4
7.
8.
9.
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(785–96):e3
10.
Accorinti M, Pesci FR, Pirraglia MP, Priori R, Pivetti-Pezzi P (2015) Multi-drug resistance and side-effects in a patient with Behçet’s disease. Clin Exp Rheumatol 33(6 Suppl 94):S141–S144PubMed
11.
Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behçet disease responsive to anakinra. Ann Intern Med 149:284–286CrossRefPubMed
12.
Emmi G, Silvestri E, Ciucciarelli L, Squatrito D, Emmi L (2014) Reply: anti-IL1 blocking agents in drug-resistant Behçet’s syndrome: our little case series. Clin Exp Rheumatol 32(4 Suppl 84):S172PubMed
13.
Emmi G, Silvestri E, Cameli AM et al (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31:152–153PubMed
14.
Cantarini L, Vitale A, Scalini P et al (2015) Anakinra treatment in drug-resistant Behçet’s disease: a case series. Clin Rheumatol 34:1293–1301CrossRefPubMed
15.
Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol 30(3 Suppl 72):S115PubMed
16.
Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R (2015) Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease. Rheumatology (Oxford) 54:1327–1328CrossRef
17.
Gül A, Tugal-Tutkun I, Dinarello CA et al (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study. Ann Rheum Dis 71:563–566CrossRefPubMed
18.
Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol 32(4 Suppl 84):S171PubMed
19.
Vitale A, Rigante D, Caso F et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology 228:211–214CrossRefPubMed
20.
Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behçet’s syndrome with refractory eye disease. Ann Rheum Dis 71:1589–1591CrossRefPubMed
21.
Caso F, Iaccarino L, Bettio S et al (2013) Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res 56:390–397CrossRefPubMed
22.
Santos-Gómez M, Calvo-Río V, Blanco R et al (2016) The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol 34(Suppl 102):34–40
23.
Calvo-Río V, de la Hera D, Beltrán-Catalán E et al (2014) Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32(4 Suppl 84):S54–S57PubMed
24.
Emmi G, Silvestri E, Squatrito D, Emmi L, Cantarini L, Prisco D (2016) Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet׳s disease. Semin Arthritis Rheum 46:e1–e2CrossRefPubMed
25.
Perez-Pampin E, Campos-Franco J, Blanco J, Mera A (2013) Remission induction in a case of refractory Behçet disease with alemtuzumab. J Clin Rheumatol 19:101–103CrossRefPubMed
26.
Deroux A, Chiquet C, Bouillet L (2016) Tocilizumab in severe and refractory Behçet’s disease: four cases and literature review. Semin Arthritis Rheum 45:733–737CrossRefPubMed
27.
Kidd DP (2015) Rituximab is effective in severe treatment-resistant neurological Behçet’s syndrome. J Neurol 262:2676–2677CrossRefPubMed
28.
Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH (2012) Epidemiology of Behçet disease. Ocul Immunol Inflamm 20:324–335CrossRefPubMed
29.
Soylu M, Ersöz TR, Erken E (1992) The association between HLA B5 and ocular involvement in Behçet’s disease in southern Turkey. Acta Ophthalmol (Copenhagen) 70:786–789CrossRef
30.
31.
Belguendouz H, Messaoudène D, Lahmar K et al (2011) Interferon-γ and nitric oxide production during Behçet uveitis: immunomodulatory effect of interleukin-10. J Interferon Cytokine Res 31:643–651CrossRefPubMed
32.
Ahn JK, Yu HG, Chung H (2006) Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol 142:429–434CrossRefPubMed
33.
Yamaoka J, Kabashima K, Kawanishi M, Toda K, Miyachi Y (2002) Cytotoxicity of IFN-gamma and TNF-alpha for vascular endothelial cell is mediated by nitric oxide. Biochem Biophys Res Commun 291:780–786CrossRefPubMed
34.
Roth E, Pircher H (2004) IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. J Immunol 172:1588–1594CrossRefPubMed
35.
Yu HG, Lee DS, Seo JM et al (2004) The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet’s uveitis. Clin Exp Immunol 137:437–443CrossRefPubMedPubMedCentral
36.
Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11:687–698CrossRefPubMed
37.
Kobayashi M, Ito M, Nakagawa A et al (2000) Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology 6:362–371CrossRef
38.
39.
Düzgün N, Ayaşlioğlu E, Tutkak H, Aydintuğ OT (2005) Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s disease. Rheumatol Int 25:1–5CrossRefPubMed
40.
Pay S, Erdem H, Pekel A et al (2006) Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet’s disease. Does interleukin-1 beta play a major role in Behçet’s synovitis? Rheumatol Int 26:608–613CrossRefPubMed
41.
Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol 29:209–210CrossRefPubMed
42.
Emmi G, Talarico R, Lopalco G et al (2016) Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol 35:1281–1286CrossRefPubMed
43.
Emmi G, Silvestri E, Squatrito D et al (2016) Long-term efficacy and safety of anakinra in a patient with Behçet’s disease and concomitant tuberculosis infection. Int J Dermatol. doi:10.​1111/​ijd.​13337 (Epub ahead of print) PubMed
44.
Fabiani C, Vitale A, Emmi G et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:191–197CrossRefPubMed
45.
Vitale A, Insalaco A, Sfriso P et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol 24(7):380
46.
Cantarini L, Lopalco G, Caso F et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev 14:1–9CrossRefPubMed
47.
48.
49.
Boulanger MJ, Chow DC, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300:2101–2104CrossRefPubMed
50.
Naka T, Narazaki M, Hirata M et al (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924–929CrossRefPubMed
51.
Yoshimura T, Sonoda KH, Ohguro N et al (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 48:347–354CrossRef
52.
Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205–210CrossRefPubMed
53.
Hirano T, Ohguro N, Hohki S et al (2012) A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22:298–302CrossRefPubMed
54.
Shapiro LS, Farrell J, Borhani Haghighi A (2012) Tocilizumab treatment for neuro-Behçet’s disease, the first report. Clin Neurol Neurosurg 114:297–298CrossRefPubMed
55.
Redondo-Pachón MD, Enríquez R, Sirvent AE et al (2013) Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behçet’s disease. Ren Fail 35:547–550CrossRefPubMed
56.
Papo M, Bielefeld P, Vallet H et al (2014) Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 32:S75–S79PubMed
57.
Diamantopoulos AP, Hatemi G (2013) Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford) 52:1923–1924CrossRef
58.
Cantarini L, Lopalco G, Vitale A et al (2015) Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab. Clin Rheumatol 34:1141–1143CrossRefPubMed
59.
Lee EG, Mickle-Kawar BM, Gallucci RM (2013) IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis. J Immunotoxicol 10:192–200CrossRefPubMed
60.
Terreaux W, Mestrallet S, Fauconier M et al (2015) Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm. Rheumatology (Oxford) 54:2111–2113CrossRef
61.
Dick AD, Tugal-Tutkun I, Foster S et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120:777–787CrossRefPubMed
62.
Direskeneli H, Fujita H, Akdis CA (2011) Regulation of TH17 and regulatory T cells in patients with Behçet disease. J Allergy Clin Immunol 128:665–666CrossRefPubMed
63.
Geri G, Terrier B, Rosenzwajg M et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 128:655–664CrossRefPubMed
64.
Chi W, Zhu X, Yang P et al (2008) Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 49:3058–3064CrossRefPubMed
65.
Kim J, Park JA, Lee EY, Lee YJ, Song YW, Lee EB (2010) Imbalance of Th17 to Th1 cells in Behçet’s disease. Clin Exp Rheumatol 28:S16–S19PubMed
66.
67.
Yamaguchi Y, Fujio K, Shoda H et al (2007) IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol 179:7128–7136CrossRefPubMed
68.
Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35:611–621CrossRefPubMed
69.
Langrish CL, Chen Y, Blumenschein WM et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240CrossRefPubMedPubMedCentral
70.
Gottlieb A, Menter A, Mendelsohn A et al (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633–640CrossRefPubMed
71.
Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP (2013) Successful long-term triple disease control by ustekinumab in a patient with Behçet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 72:626–627CrossRefPubMed
72.
Buggage RR, Levy-Clarke G, Sen HN et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm 15:63–70CrossRefPubMedPubMedCentral
73.
Diao L, Hang Y, Othman AA et al (2016) Population PK-PD analyses of CD25 occupancy, CD56 (bright) NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. Br J Clin Pharmacol 82:1333–1342CrossRefPubMedPubMedCentral
74.
Evereklioglu C, Er H, Türköz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediat Inflamm 11:87–93CrossRef
75.
Yücel A, Dilek K, Saba D, Ozçimen AA, Yurtkuran M, Oral HB (2013) Interleukin-2 gene polymorphism in Turkish patients with Behçet’s disease and its association with ocular involvement. Int J Immunogenet 40:349–355CrossRefPubMed
76.
Wroblewski K, Sen HN, Yeh S et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 46:322–328CrossRefPubMedPubMedCentral
77.
Kempen JH, Gangaputra S, Daniel E et al (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146(802–12):e1
78.
Gheita TA, Raafat H, Khalil H, Hussein H (2013) Serum level of APRIL/BLyS in Behçet’s disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol 23:542–546CrossRefPubMed
79.
Shaker OG, Tawfic SO, El-Tawdy AM, El-Komy MH, El Menyawi M, Heikal AA (2014) Expression of TNF-α, APRIL and BCMA in Behçet’s disease. J Immunol Res 2014:380405CrossRefPubMedPubMedCentral
80.
Suh CH, Park YB, Song J, Lee CH, Lee SK (2001) Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet’s disease. Arthritis Rheum 44:1707–1712CrossRefPubMed
81.
Sadreddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod Rheumatol 18:306–308CrossRefPubMed
82.
Zhao BH, Oswald AE (2014) Improved clinical control of a challenging case of Behçet’s disease with rituximab therapy. Clin Rheumatol 33:149–150CrossRefPubMed
83.
84.
Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246–252CrossRefPubMed
85.
Caso F, Rigante D, Vitale A et al (2015) Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt–Koyanagi–Harada disease. Clin Rheumatol 34:1817–1820CrossRefPubMed
86.
87.
Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42:1539–1544CrossRef
88.
Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR (2015) Alemtuzumab as remission induction therapy in Behçet disease: a 20-year experience. J Rheumatol 42:1906–1913CrossRefPubMed
89.
Kirk AD, Hale DA, Swanson SJ, Mannon RB (2006) Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 6:1084–1085CrossRefPubMed
90.
Daniels GH, Vladic A, Brinar V et al (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80–89CrossRefPubMed
91.
Schwartzman S, Schwartzman M (2015) The use of biologic therapies in uveitis. Clin Rev Allergy Immunol 49:307–316CrossRefPubMed
92.
Lopalco G, Fabiani C, Sota J et al (2017) IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol 36:1459–1469CrossRefPubMed
Metadata
Title
Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review
Authors
Jurgen Sota
Donato Rigante
Giuseppe Lopalco
Bruno Frediani
Rossella Franceschini
Mauro Galeazzi
Florenzo Iannone
Gian Marco Tosi
Claudia Fabiani
Luca Cantarini
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2018
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3775-5

Other articles of this Issue 1/2018

Rheumatology International 1/2018 Go to the issue

Genes and Disease

Does thiol–disulphide balance show oxidative stress in different MEFV mutations?

Comorbidities

Cardiovascular disease in patients with autoinflammatory syndromes

Original Article

Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency

Genes and Disease

One novel and two uncommon MEFV mutations in Japanese patients with familial Mediterranean fever: a clinicogenetic study

Review Article

Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes

Observational Research

An investigation of the independent risk factors that differentiate gout from pseudogout in patients with crystal-induced acute arthritis: a cross-sectional study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits